Multi-Institutional Experience of Stereotactic Body Radiotherapy for Large (≥5 Centimeters) Non-Small Cell Lung Tumors
Multi-Institutional Experience of Stereotactic Body Radiotherapy for Large (≥5 Centimeters) Non-Small Cell Lung Tumors
复制标题
DOI：
10.1002/cncr.30375
复制
发表时间：
2017-02-15
期刊：
影响因子：
6.2
通讯作者：
Simone, Charles B., II
中科院分区：
文献类型：
--
作者：
Verma, Vivek;Shostrom, Valerie K.;Simone, Charles B., II
背景技术背景：立体定向体部放疗（SBRT）是非手术、早期非小细胞肺癌（NSCLC）患者的标准治疗，测量≥ 5 cm，定义相当少，现有文献仅限于小型、单机构报告。目前的多机构研究报告了评估迄今为止报告的最大此类人群的结果。方法：评估了接受SBRT的原发性NSCLC患者的临床/治疗特征、结局、毒性和失败模式，这些患者测量>= 5 cm，无远处/淋巴结转移证据，使用
BACKGROUND: Stereotactic body radiotherapy (SBRT) is the standard of care for patients with nonoperative, early-stage non-small cell lung cancer (NSCLC) measuring = 5 cm is considerably less defined, with the existing literature limited to small, single-institution reports. The current multi-institutional study reported outcomes evaluating the largest such population reported to date. METHODS: Clinical/treatment characteristics, outcomes, toxicities, and patterns of failure were assessed in patients with primary NSCLC measuring >= 5 cm without evidence of distant/lymph node metastasis who underwent SBRT using